GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Madeleine Harrison who wrote (391)	3/7/1999 12:27:00 PM
From: DanZ	Read Replies (2) of 5582

Madly, The primary reason that Quigley did well with Cold Eeze can be found on their web site. Quoting from quigleyco.com, "For the first calendar year since the second study proving the efficacy of Cold-Eeze®, sales and earnings soared from prior fiscal years that included a maximum of $1 million in sales. Included in the $70.2 million of sales were approximately $12 million of product shipments resulting from and order backlog (initial pipeline fill) from the last quarter of 1996." The "second study" that they are referring to was a randomized double-blind placebo-controlled study called "Zinc Gluconate Lozenges for Treating the Common Cold". The results of the study were published in the Annals of Internal Medicine – Vol. 125 No. 2., on July 15, 1996. The media picked up on it and sales of Cold Eeze went through the roof, rising from only $1 million to $70 million in one year. Geltech has already submitted the results of their randomized double-blind placebo-controlled study on Zicam to the New England Journal of Medicine and a publication decision is expected in April or May. The average turnaround time is less than 3-4 months so April is not an unreasonable expectation. If the NEJM publishes the study, you can bet your bottom dollar that GumTech's stock and sales of Zicam will probably soar. The resulting publicity on television, radio, newspapers, magazines, and word of mouth could be huge. Zicam could become a household name overnight just like other products that had a media blitz behind them. I hope this doesn't come across as hype. I'm simply stating an opinion based on what has happened to other products in similar situations. I believe that the stock will move up in anticipation of the NEJM decision and in anticipation of excellent first quarter sales and earnings. This is why I'm not selling my stock and recommend it for purchase at this time. Dan

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next